BeOne Medicines Ltd. Class A
688235.SS
Price:
$274
Market Cap:
$40.69B
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small mole...[Read more]
Industry
Biotechnology
IPO Date
2021-12-15
Stock Exchange
SHH
Ticker
688235.SS
PE Ratio
[1.01K]
ROE
[-5.64%]
Current Ratio
[1.95]
Dividend Yield
[0%]
Enterprise Value
[38.96B]
Dividend History
The Current Ratio as of December 2025 (TTM) for BeOne Medicines Ltd. Class A (688235.SS) is 1.95
According to BeOne Medicines Ltd. Class A’s latest financial reports and current stock price. The company's current Current Ratio is 1.95. This represents a change of 2.01% compared to the average of 1.91 of the last 4 quarters.
BeOne Medicines Ltd. Class A (688235.SS) Historical Current Ratio (quarterly & annually)
How has 688235.SS Current Ratio performed in the past?
The mean historical Current Ratio of BeOne Medicines Ltd. Class A over the last ten years is 4.88. The current 1.95 Current Ratio has changed 3.90% with respect to the historical average. Over the past ten years (40 quarters), 688235.SS's Current Ratio was at its highest in in the March 2016 quarter at 15.91. The Current Ratio was at its lowest in in the December 2024 quarter at 1.80.
Average
4.88
Median
4.36
Minimum
1.80
Maximum
10.68
BeOne Medicines Ltd. Class A (688235.SS) Current Ratio by Quarter and Year
Discovering the peaks and valleys of BeOne Medicines Ltd. Class A Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 253.46%
Maximum Annual Current Ratio = 10.68
Minimum Annual Increase = -48.02%
Minimum Annual Current Ratio = 1.80
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 1.80 | -22.39% |
| 2023 | 2.32 | -34.51% |
| 2022 | 3.55 | -25.51% |
| 2021 | 4.76 | 3.17% |
| 2020 | 4.61 | 12.54% |
| 2019 | 4.10 | -48.02% |
| 2018 | 7.89 | 29.50% |
| 2017 | 6.09 | -42.97% |
| 2016 | 10.68 | 253.46% |
| 2015 | 3.02 | -14.39% |
BeOne Medicines Ltd. Class A (688235.SS) Average Current Ratio
How has 688235.SS Current Ratio performed in the past?
The current Current Ratio of BeOne Medicines Ltd. Class A (688235.SS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.56
5-year avg
3.41
10-year avg
4.88
BeOne Medicines Ltd. Class A (688235.SS) Current Ratio vs. Peers
How is 688235.SS’s Current Ratio compared to its peers?
BeOne Medicines Ltd. Class A’s Current Ratio is less than WuXi AppTec Co., Ltd. (2.08), less than Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (2.54), less than Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (4.26), greater than Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (0.87), less than Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (2.05), greater than RemeGen Co Ltd (0.96), greater than Shanghai Junshi Biosciences Co., Ltd. (1.62), less than Nanjing Vazyme Biotech Co., Ltd. (3.73), greater than Suzhou Zelgen Biopharmaceuticals Co., Ltd. (1.85), greater than Sinocelltech Group Limited (0.61),
| Company | Current Ratio | Market cap |
|---|---|---|
| 2.08 | $228.70B | |
| 2.54 | $240.03B | |
| 4.26 | $58.73B | |
| 0.87 | $58.16B | |
| 2.05 | $37.09B | |
| 0.96 | $44.74B | |
| 1.62 | $35.07B | |
| 3.73 | $8.01B | |
| 1.85 | $26.82B | |
| 0.61 | $19.85B |
Build a custom stock screener for BeOne Medicines Ltd. Class A (688235.SS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeOne Medicines Ltd. Class A using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
BeOne Medicines Ltd. Class A (688235.SS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like BeOne Medicines Ltd. Class A or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the Current Ratio?
How can you use the Current Ratio?
What is BeOne Medicines Ltd. Class A's Current Ratio?
How is the Current Ratio calculated for BeOne Medicines Ltd. Class A (688235.SS)?
What is the highest Current Ratio for BeOne Medicines Ltd. Class A (688235.SS)?
What is the 3-year average Current Ratio for BeOne Medicines Ltd. Class A (688235.SS)?
What is the 5-year average Current Ratio for BeOne Medicines Ltd. Class A (688235.SS)?
How does the current Current Ratio for BeOne Medicines Ltd. Class A (688235.SS) compare to its historical average?